News Tag: Other Corporate Information

The subscription price for exercise of warrants of series TO10B in iZafe Group AB has been determined to SEK 0.26 per share of series B and the exercise period begins tomorrow September 27, 2022

iZafe Group AB ("iZafe" or the "Company") issued, in connection with a rights issue in the fourth quarter of 2021, warrants of series TO10B. Each warrant gives the right to subscribe for one (1) new share of series B in the Company. The subscription price has been set to SEK 0.26 per each share of series B. The exercise period for warrants of series TO10B runs from September 27, 2022, up to and including October 11, 2022.

Each warrant gives the right to subscribe for one (1) new share of series B in the Company. The subscription price for the warrants of series TO10B shall correspond to 70 percent of the volume-weighted average price of the Company's share of series B on Nasdaq First North Premier Growth Market during the measurement period from and including September 12, 2022, up to and including September 23, 2022. However, not lower than the quota value for the Company's share and not higher than SEK 2.25 per share. The volume-weighted average price of the Company's share of series B during the measurement period amounted to approximately SEK 0.37. Thus, the subscription price is determined to SEK 0.26. The exercise period for warrants of series TO10B runs from September 27, 2022, up to and including October 11, 2022. Complete terms and conditions for the warrants of series TO10B are available on the Company's website, www.izafegroup.com.

Summarized terms for the warrants of series TO10B:

Exercise period: September 27, 2022 – October 11, 2022.

Exercise price: SEK 0.26 per share of series B.

Issue size: 35,435,674 warrants of series TO10B, which entitles to subscription of 35,435,674 shares of series B. If all the warrants are exercised, The Company will receive approximately SEK 9.2 million before issuing costs.

Last day for trading warrants of series TO10B: October 7, 2022.

Share capital and dilution: If all warrants are exercised the share capital will increase with SEK 7,087,134.80, from SEK 14,174,861.60 to SEK 21,261,996.40. If all warrants are exercised the number of shares will increase with 35,435,674 shares of series B, in total the number of shares in the Company will increase from 70,874,308 shares to 106,309,982 shares (600,000 shares of series A and 105,709,982 shares of series B). The dilution at full exercise of all warrants amounts to approximately 33.33 percent of the number of shares and 31.72 percent of the votes in the Company.
Note that the warrants of series TO10B that are not exercised at the latest October 11, 2022, or sold at the latest October 7, 2022, will expire without value. For the warrants not to lose their value, the holder must actively subscribe for new shares or sell the warrants.

Advisors
Mangold Fondkommission AB is the financial advisor and Eversheds Sutherland Advokatbyrå AB is the legal advisor to the Company in connection with the exercise of the warrants of series TO10B.

Contacts

Anders Segerström, Chief Executive Officer 
E-mail:
Phone number: +46 70-875 14 12

iZafe Group AB (publ.)
Södra Fiskartorpsvägen 20
114 33 Stockholm

E-mail: 
www.izafe.se/investor-relations/

About Us

iZafe Group is a Swedish Life-Science company that develops and markets medical and digital security solutions to create safer drug handling at home. The company’s digital medication dispenser Dosell reduces the risk of incorrect medication, increases security for family and relatives and relieves public care personnel. The products form a holistic concept that facilitates patient medication and gives those who are treated at home better conditions for a happy and safe life. Customers today consist of public and private care providers in Sweden, the Nordic countries and globally. iZafe Group sells primarily through well-established partners who already have long and deep customer relationships with the priority customer groups. The head office is located in Stockholm.

The company is listed on the NASDAQ First North Premier Growth Market. FNCA Sweden AB is the company's Certified Adviser. Phone: +46 (0) 8 528 00 399. E-mail: . Further information is available at www.izafe.se/investor-relations/.

Attachments

The subscription price for exercise of warrants of series TO10B in iZafe Group AB has been determined to SEK 0.26 per share of series B and the exercise period begins tomorrow September 27, 2022

The subscription price for exercise of warrants of series TO10B in iZafe Group AB has been determined to SEK 0.26 per share of series B and the exercise period begins tomorrow September 27, 2022

iZafe’s election committee proposes Björn Rosengren as new chairman of the board

iZafe Group (publ) hereby announces that the nomination committee proposes that Björn Rosengren be elected as the new chairman of the board at an extra general meeting. This means that Björn Rosengren is proposed to take over as new chairman after Joachim Källsholm.

Björn Rosengren has a wide range of skills and extensive experience from both business and the public sector, including as minister of business, governor and advisor to Kinnevik. Today he mainly works as a board professional in both listed and unlisted companies. Some of the companies where he is chairman of the board are Fastator, listed on Mid Cap, Studentbostäder i Norden at First North and the Norwegian-Swedish Chamber of Commerce.

"We are facing a future where the population is getting older and the pressure on healthcare is increasing. iZafe is an important piece of the puzzle to create better and safer care through medical and digital security solutions. Where I see great potential with the pharmaceutical robot Dosell on the international market. I feel both happy and honored and look forward to contributing and following the company's exciting journey forward towards new levels, says Björn Rosengren, proposed new chairman of iZafe Group.

The chairman of the selection committee, Sten Röing, comments:
"Björn Rosengren has solid experience in creating value and consensus between management and owners regarding goals and priorities. We are convinced that he will contribute to continuing to develop iZafe and be involved in the work around the company's positive growth and future."

The selection committee consists of Sten Röing, Göran Sjönell and Carl Johan Merner.

The nomination committee's complete proposal will be presented in the notice to the extra general meeting.

Contacts

Anders Segerström, Chief Executive Officer 
E-mail:
Phone number: +46 70-875 14 12

iZafe Group AB (publ.)
Södra Fiskartorpsvägen 20
114 33 Stockholm

E-mail: 
www.izafe.se/investor-relations/

About Us

iZafe Group is a Swedish Life-Science company that develops and markets medical and digital security solutions to create safer drug handling at home. The company’s digital medication dispenser Dosell reduces the risk of incorrect medication, increases security for family and relatives and relieves public care personnel. The products form a holistic concept that facilitates patient medication and gives those who are treated at home better conditions for a happy and safe life. Customers today consist of public and private care providers in Sweden, the Nordic countries and globally. iZafe Group sells primarily through well-established partners who already have long and deep customer relationships with the priority customer groups. The head office is located in Stockholm.

The company is listed on the NASDAQ First North Premier Growth Market. FNCA Sweden AB is the company's Certified Adviser. Phone: +46 (0) 8 528 00 399. E-mail: . Further information is available at www.izafe.se/investor-relations/.

Image Attachments

Bjorn Rosengren

Attachments

iZafe's election committee proposes Björn Rosengren as new chairman of the board

iZafe's election committee proposes Björn Rosengren as new chairman of the board
Bjorn Rosengren

The implementation of Dosell started again with municipalities

iZafe Group (publ.) hereby announces that the partner Careium AB is today starting the implementation of Dosell in a municipality.

"As we communicated on June 8 and that in connection with delivery challenges and approaching holiday times, the majority of municipalities chose to postpone the introduction until after the summer. Now the municipalities are finally getting time to start the implementation and the first to go is our partner Careium AB. Together with our partners, we are working hard to ensure that the municipalities prioritize the start-up of our medicinal robot Dosell here this fall." Says Anders Segerström, CEO of iZafe Group

About Careium
Careium is today the market leader in welfare technology in Europe and approximately 400,000 people use their services. The vast majority of these are connected to one of their six alarm centers in Sweden, Norway and the United Kingdom. The alarm centers receive more than 30,000 alarms a day.
Doro Care recently changed its name to Careium. Doro acquired Caretech in 2014, which became the starting point for what today is Careium.
 
About Dosell
The medicinal robot Dosell is a Swedish-made digital aid for safer medication at home and for people living in nursing homes. Dosell is integrated into welfare platforms and is sold as one of several integrated digital aids via partners.
In a Swedish report, it is estimated that 3,000 Swedes die annually from drug-related injuries and that 6–16 percent of hospital admissions are drug-related. The costs for drug-related injuries that can be avoided are estimated at SEK 5.6–24.6 billion per year.
Dosell notifies the patient when it's time to take the medicine, and if the medicine is not taken despite the reminders, Dosell alerts healthcare professionals or relatives who can quickly prevent an injury and improve compliance, thus minimizing drug-related injuries.
Read more at www.dosell.se

Contacts

Anders Segerström, Chief Executive Officer 
E-mail:
Phone number: +46 70-875 14 12

iZafe Group AB (publ.)
Södra Fiskartorpsvägen 20
114 33 Stockholm

E-mail: 
www.izafe.se/investor-relations/

About Us

iZafe Group is a Swedish Life-Science company that develops and markets medical and digital security solutions to create safer drug handling at home. The company’s digital medication dispenser Dosell reduces the risk of incorrect medication, increases security for family and relatives and relieves public care personnel. The products form a holistic concept that facilitates patient medication and gives those who are treated at home better conditions for a happy and safe life. Customers today consist of public and private care providers in Sweden, the Nordic countries and globally. iZafe Group sells primarily through well-established partners who already have long and deep customer relationships with the priority customer groups. The head office is located in Stockholm.

The company is listed on the NASDAQ First North Premier Growth Market. FNCA Sweden AB is the company's Certified Adviser. Phone: +46 (0) 8 528 00 399. E-mail: . Further information is available at www.izafe.se/investor-relations/.

Attachments

The implementation of Dosell started again with municipalities

The implementation of Dosell started again with municipalities

iZafe begins cooperation with the welfare platform Avanto Care

iZafe Group (publ.) hereby announces that iZafe has signed a cooperation agreement with the welfare platform Avanto Care to be able to offer customers more proactive care.

"In order for future care to be able to work smart with all the advantages that digital tools provide, platforms are needed that connect all the data that the customer receives from them. Avanto Care is a platform that, in a neat and educational way, presents useful insights and action proposals linked to the data points that come in from various digital tools and sensors. In addition to providing better care, this will also in the long term enable a new type of income source for Dosell and our upcoming total solution around medication and compliance that we will offer in connection with the acquisition of Pilloxa." Says Anders Segerström CEO, iZafe Group

"The ability for caregivers and care recipients to follow medication is important for healthy ageing. We at Avanto Care see that the collaboration with iZafe and their drugrobot Dosell creates new opportunities for quality follow-up. Through the collaboration, our customers can monitor the effect of interventions and create decision-making bases for proactive interventions in health and social care." Says Mikael Karlsson, CEO, Avanto Care

The collaboration means that iZafe's products are integrated with Avanto Care's platform. This means that customers who have iZafe's products can also use Avanto Care's platform. It creates the conditions for iZafe's customers to work more proactively by seeing trends and proposed measures linked to the user's medication.

Read more about Avanto Care here: https://www.avantocare.com

Contacts

Anders Segerström, Chief Executive Officer 
E-mail:
Phone number: +46 70-875 14 12

iZafe Group AB (publ.)
Södra Fiskartorpsvägen 20
114 33 Stockholm

E-mail: 
www.izafe.se/investor-relations/

About Us

iZafe Group is a Swedish Life-Science company that develops and markets medical and digital security solutions to create safer drug handling at home. The company’s digital medication dispenser Dosell reduces the risk of incorrect medication, increases security for family and relatives and relieves public care personnel. The products form a holistic concept that facilitates patient medication and gives those who are treated at home better conditions for a happy and safe life. Customers today consist of public and private care providers in Sweden, the Nordic countries and globally. iZafe Group sells primarily through well-established partners who already have long and deep customer relationships with the priority customer groups. The head office is located in Stockholm.

The company is listed on the NASDAQ First North Premier Growth Market. FNCA Sweden AB is the company's Certified Adviser. Phone: +46 (0) 8 528 00 399. E-mail: . Further information is available at www.izafe.se/investor-relations/.

Attachments

iZafe begins cooperation with the welfare platform Avanto Care

iZafe begins cooperation with the welfare platform Avanto Care

iZafe’s board chairman Joachim Källsholm resigns at his own request

iZafe Group (publ.) has today notified the board of its decision to resign as chairman of the board for iZafe Group.

"In connection with the upcoming acquisition and the fact that I myself have many new assignments, I have finally made the choice to resign. At the stage iZafe is in now, a chairman is needed who has more time to actively work with the company than I can currently contribute. I am proud of the parts that have taken place in the past year and look forward to following iZafe's future journey. " Says Joachim Källsholm Chairman, iZafe Group

Contacts

Anders Segerström, Chief Executive Officer 
E-mail:
Phone number: +46 70-875 14 12

iZafe Group AB (publ.)
Södra Fiskartorpsvägen 20
114 33 Stockholm

E-mail: 
www.izafe.se/investor-relations/

About Us

iZafe Group is a Swedish Life-Science company that develops and markets medical and digital security solutions to create safer drug handling at home. The company’s digital medication dispenser Dosell reduces the risk of incorrect medication, increases security for family and relatives and relieves public care personnel. The products form a holistic concept that facilitates patient medication and gives those who are treated at home better conditions for a happy and safe life. Customers today consist of public and private care providers in Sweden, the Nordic countries and globally. iZafe Group sells primarily through well-established partners who already have long and deep customer relationships with the priority customer groups. The head office is located in Stockholm.

The company is listed on the NASDAQ First North Premier Growth Market. FNCA Sweden AB is the company's Certified Adviser. Phone: +46 (0) 8 528 00 399. E-mail: . Further information is available at www.izafe.se/investor-relations/.

Attachments

iZafe's board chairman Joachim Källsholm resigns at his own request

iZafe's board chairman Joachim Källsholm resigns at his own request

iZafe Group invites shareholders and other stakeholders to a Q&A session in connection with the publication of the second quarter report

iZafe Group AB (publ) – announces that in connection with the interim report for the second quarter of 2022, which will be published at 08:30 CET on August 26, 2022, shareholders, media, and other stakeholders will be given the opportunity to ask questions to the company.

The questions will be answered by CEO Anders Segerström and published on iZafe Group's investor page on September 2, 2022, under the heading financial reports, investor questions.
Please send your questions to before 10:00 CET (10 a.m.) on August 30, 2022.

Contacts

Anders Segerström, Chief Executive Officer 
E-mail:
Phone number: +46 70-875 14 12

iZafe Group AB (publ.)
Södra Fiskartorpsvägen 20
114 33 Stockholm

E-mail: 
www.izafe.se/investor-relations/

About Us

iZafe Group is a Swedish Life-Science company that develops and markets medical and digital security solutions to create safer drug handling at home. The company’s digital medication dispenser Dosell reduces the risk of incorrect medication, increases security for family and relatives and relieves public care personnel. The products form a holistic concept that facilitates patient medication and gives those who are treated at home better conditions for a happy and safe life. Customers today consist of public and private care providers in Sweden, the Nordic countries and globally. iZafe Group sells primarily through well-established partners who already have long and deep customer relationships with the priority customer groups. The head office is located in Stockholm.

The company is listed on the NASDAQ First North Premier Growth Market. FNCA Sweden AB is the company's Certified Adviser. Phone: +46 (0) 8 528 00 399. E-mail: . Further information is available at www.izafe.se/investor-relations/.

Attachments

iZafe Group invites shareholders and other stakeholders to a Q&A session in connection with the publication of the second quarter report

iZafe Group invites shareholders and other stakeholders to a Q&A session in connection with the publication of the second quarter report

Live interview regarding the acquisition of Pilloxa

iZafe Group (publ.) hereby invites you to a live interview with Pilloxa's CEO Helena Rönnqvist and iZafe Group's CEO Anders Segerström on Wednesday, August 24 at 2 p.m. due to the fact that iZafe has signed a letter of intent with Pilloxa to acquire 100 percent of the shares in Pilloxa.

Read the full news here.

During the interview, all shareholders and stakeholders will get a more in-depth understanding of the rationale behind the acquisition, about Pilloxa as a company and what the acquisition means for the future iZafe Group.

Links to the interview can be found here
LinkedIn
Facebook

Contacts

Anders Segerström, Chief Executive Officer 
E-mail:
Phone number: +46 70-875 14 12

iZafe Group AB (publ.)
Södra Fiskartorpsvägen 20
114 33 Stockholm

E-mail: 
www.izafe.se/investor-relations/

About Us

iZafe Group is a Swedish Life-Science company that develops and markets medical and digital security solutions to create safer drug handling at home. The company’s digital medication dispenser Dosell reduces the risk of incorrect medication, increases security for family and relatives and relieves public care personnel. The products form a holistic concept that facilitates patient medication and gives those who are treated at home better conditions for a happy and safe life. Customers today consist of public and private care providers in Sweden, the Nordic countries and globally. iZafe Group sells primarily through well-established partners who already have long and deep customer relationships with the priority customer groups. The head office is located in Stockholm.

The company is listed on the NASDAQ First North Premier Growth Market. FNCA Sweden AB is the company's Certified Adviser. Phone: +46 (0) 8 528 00 399. E-mail: . Further information is available at www.izafe.se/investor-relations/.

Attachments

Live interview regarding the acquisition of Pilloxa

Live interview regarding the acquisition of Pilloxa

Continued high demand for the consumer version of Dosell

Stockholm – iZafe Group (publ.) Announces today that it has delivered an additional 100 Dosell units to Apoteket AB in addition to deliveries of 130 units earlier in June. A total of 230 units were now delivered during the month of June to Apoteket AB.

– The great demand is a proof that more and more people want to use new digital technology in their daily lives to free up time and ensure compliance in their or their relatives medication. It also shows that Apoteket's online store is a good way to reach those who want safer drug handling at home, says Anders Segerström, CEO of iZafe Group AB.
 
This summer, iZafe will release a new feature in the Dosell app that makes it even easier to follow up on your own or relatives medication.
 
– This new function makes it even easier to follow your own or your relatives medication. We also know that the opportunity to test Dosell contributes to the experience of what a difference Dosell really makes. Therefore, we will in the TV commercial highlight that you get the opportunity to send Dosell back within 30 days if you are not satisfied with the product. This is so that even more people will dare to take the step of testing new digital technology that frees up time and ensures compliance in their or their relatives medication, says Anders Segerström, CEO of iZafe Group AB.
 
– The consumer version of Dosell is unique and currently Europe's only pharmaceutical robot for the private market based on dose bags. This has attracted the attention of several players where dialogues are now being conducted to launch Dosell for consumers in several markets in Europe, says Anders Segerström, CEO of iZafe Group AB.

Contacts

Anders Segerström, Chief Executive Officer 
E-mail:
Phone number: +46 70-875 14 12

iZafe Group AB (publ.)
Södra Fiskartorpsvägen 20
114 33 Stockholm

E-mail: 
www.izafe.se/investor-relations/

About Us

iZafe Group is a Swedish Life-Science company that develops and markets medical and digital security solutions to create safer drug handling at home. The company’s digital medication dispenser Dosell reduces the risk of incorrect medication, increases security for family and relatives and relieves public care personnel. The products form a holistic concept that facilitates patient medication and gives those who are treated at home better conditions for a happy and safe life. Customers today consist of public and private care providers in Sweden, the Nordic countries and globally. iZafe Group sells primarily through well-established partners who already have long and deep customer relationships with the priority customer groups. The head office is located in Stockholm.

The company is listed on the NASDAQ First North Premier Growth Market. FNCA Sweden AB is the company's Certified Adviser. Phone: +46 (0) 8 528 00 399. E-mail: . Further information is available at www.izafe.se/investor-relations/.

Image Attachments

Dosell Ny Funktion

Attachments

Continued high demand for the consumer version of Dosell

Continued high demand for the consumer version of Dosell
Dosell Ny Funktion

New delivery of Dosell to Apoteket AB

iZafe Group (publ.) hereby announces that a large amount of Dosell will be delivered from the factory to Apoteket AB today, after being out of stock for about 6 weeks.

“We are pleased to be able to refill Apoteket AB's warehouse after Dosell has been sold out for a period. As more and more people use Dosell, we work focused on securing production and improving its functionality.

The latest update contained a bug that caused Dosell to restart from time to time. This has led to delays in deliveries, both of the consumer version and the corporate version, which has affected the municipalities' planned project starts of Dosell. As we approach the holiday season, most municipalities have chosen to postpone the introduction until after the summer.

The new, updated version of Dosell includes several new improvements and features that will improve both the user experience and reliability. Consumers using Dosell will not be affected as the new software is updated over the cloud.” Says Anders Segerström, CEO of iZafe Group AB.

About Dosell
The pharmaceutical robot Dosell is a Swedish-made digital aid for safer medication at home and for people living in nursing homes. Dosell is integrated into welfare platforms and is sold as one of several integrated digital aids via partners.
It is estimated that 3,000 Swedes die each year from medication-related injuries and 6–16 percent of hospital admissions are medication-related, according to a compilation from the Swedish National Board of Health and Welfare.
Dosell notifies the patient when it's time to take the medicine, and if the medicine is not taken despite the reminders, Dosell alerts healthcare professionals or relatives who can quickly prevent an injury and improve compliance, thus minimizing medication-related injuries.
Read more at www.dosell.se

Contacts

Anders Segerström, Chief Executive Officer 
E-mail:
Phone number: +46 70-875 14 12

iZafe Group AB (publ.)
Södra Fiskartorpsvägen 20
114 33 Stockholm

E-mail: 
www.izafe.se/investor-relations/

About Us

iZafe Group is a Swedish Life-Science company that develops and markets medical and digital security solutions to create safer drug handling at home. The company’s digital medication dispenser Dosell reduces the risk of incorrect medication, increases security for family and relatives and relieves public care personnel. The products form a holistic concept that facilitates patient medication and gives those who are treated at home better conditions for a happy and safe life. Customers today consist of public and private care providers in Sweden, the Nordic countries and globally. iZafe Group sells primarily through well-established partners who already have long and deep customer relationships with the priority customer groups. The head office is located in Stockholm.

The company is listed on the NASDAQ First North Premier Growth Market. FNCA Sweden AB is the company's Certified Adviser. Phone: +46 (0) 8 528 00 399. E-mail: . Further information is available at www.izafe.se/investor-relations/.

Attachments

New delivery of Dosell to Apoteket AB

New delivery of Dosell to Apoteket AB

Business unit manager at Dosell buys shares in iZafe Group AB

Dosell's business unit manager, Henrik Windahl, has acquired 319,841 shares in the company.

Henrik Windahl, who recently began his employment as department manager for Dosell in iZafe Group's wholly owned subsidiary Dosell AB, has today acquired 319,941 Series B shares in the company to a value of SEK 163,534 (SEK 0.51 / pc).

Contacts

Anders Segerström, Chief Executive Officer 
E-mail:
Phone number: +46 70-875 14 12

iZafe Group AB (publ.)
Södra Fiskartorpsvägen 20
114 33 Stockholm

E-mail: 
www.izafe.se/investor-relations/

About Us

iZafe Group is a Swedish Life-Science company that develops and markets medical and digital security solutions to create safer drug handling at home. The company’s digital medication dispenser Dosell reduces the risk of incorrect medication, increases security for family and relatives and relieves public care personnel. The products form a holistic concept that facilitates patient medication and gives those who are treated at home better conditions for a happy and safe life. Customers today consist of public and private care providers in Sweden, the Nordic countries and globally. iZafe Group sells primarily through well-established partners who already have long and deep customer relationships with the priority customer groups. The head office is located in Stockholm.

The company is listed on the NASDAQ First North Premier Growth Market. FNCA Sweden AB is the company's Certified Adviser. Phone: +46 (0) 8 528 00 399. E-mail: . Further information is available at www.izafe.se/investor-relations/.

Attachments

Business unit manager at Dosell buys shares in iZafe Group AB

Business unit manager at Dosell buys shares in iZafe Group AB
Webbdesign av Comlog Webbyrå Stockholm